P-301 Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma

Ioannis Ntanasis‐Stathopoulos; Panagiotis Malandrakis; Despina Fotiou; Magdalini Migkou; Μαρία Ρούσσου; Evangelos Eleutherakis‐Papaiakovou; Foteini Theodorakakou; Vassiliki Spiliopoulou; Efstathios Kastritis; Evangelos Terpos; Meletios A Dimopoulos; Maria Gavriatopoulou

doi:10.1016/s2152-2650(23)01919-5

Related publications

Article2023

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Μαρία Ρούσσου, Evangelos Eleutherakis‐Papaiakovou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Maria Gavriatopoulou

Article2023

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA

Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Μαρία Ρούσσου, Evangelos Eleutherakis‐Papaiakovou, Foteini Theodorakakou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Maria Gavriatopoulou

Letter2024

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

María‐Victoria Mateos, Katja Weisel, Evangelos Terpos, Sossana Delimpasi, Efstathios Kastritis, Elena Zamagni, Michel Delforge, Enrique M. Ocio, Eirini Katodritou, Francesca Gay, Alessandra Larocca, Xavier Leleu, Paula Rodríguez‐Otero, Fredik Schjesvold, Michèle Cavo, Meletios A Dimopoulos

Article2023

P-238 A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/ refractory multiple myeloma (RRMM)

Michèle Cavo, Michel Delforge, Meletios A Dimopoulos, Fernando Escalante, Malin Hultcrantz, David Kleinman, Hans C. Lee, Ravi Vij, Nirali Kotowsky, Leena Camadoo-O'Byrne, Jacopo Bitetti, Tim D'Estrube, Mark Fry, Carla Y. Vossen

Article2020

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A Dimopoulos, Philippe Moreau, David Dingli, Lee‐Jen Wei, Joshua Richter, Noa Biran, David S. Siegel, William M. Reichmann, Lingling Li, Shijie Tang, Jean‐Richard Saint‐Martin, Anita Joshi, Michael Kauffman, Jatin J. Shah, Sharon Shacham, Sagar Lonial

P-301 Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma

Discussion(0)

Related publications

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

P-238 A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/ refractory multiple myeloma (RRMM)

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma